Literature DB >> 23640566

Tophaceous gout of the spine masquerading as spondylodiscitis.

R Krishnakumar1, J Renjitkumar.   

Abstract

Entities:  

Mesh:

Year:  2013        PMID: 23640566      PMCID: PMC3705668     

Source DB:  PubMed          Journal:  Indian J Med Res        ISSN: 0971-5916            Impact factor:   2.375


× No keyword cloud information.
A 51-year old male presented to the spine unit, department of Orthopaedics of Amrita Institute of Medical Sciences, Cochin, India, with chronic back pain with difficulty in walking for the past six months. On evaluation, he had bilateral arthritis of the knees and right elbow. He had severe tenderness at the lumbosacral junction with severe pain on attempted spinal movement. Laboratory investigations showed elevated ESR and C-reactive protein (CRP). MRI showed lytic destruction of antero inferior end plates of L5 vertebral body with retropulsion of L5 vertebral body into the spinal canal causing significant compression of cadua equine and hyperintensity in the intervertebral disc space at L5-S1 level in T2 weighted sagittal image (Fig. 1). Post contrast MRI study showed peripheral enhancement of L5-S1 intervertebral disc (Fig. 2). Therefore, he was diagnosed to have infectious spondylodiscitis at L5-S1 with cauda equina compression. He underwent posterior decompression and interbody fusion. Intraoperatively L5-S1 disc showed degeneration and was speckled with whitish chalky material. The histopathological examination of the disc material demonstrated fibroblasts, intense inflammatory infiltrate composed of lymphocytes and foreign body type of giant cells around a few long slender needle shaped crystals suggestive of tophaceous gout (Fig. 3). Post-operative serum uric acid was grossly elevated to 19.1 mg/dl. He was medically managed with allopurinol 300 mg/day with non-steroidal anti-inflammatory drugs (NSAIDS) to prevent flare up reaction following surgery. Retrospective evaluation revealed gouty tophi on the ears. The patient developed wound infection and Escherichia coli septicaemia during the postoperative period and expired one week later.
Fig. 1

T2W image showing hyperintense L5-S1 disc

Fig. 2

Axial MRI with contrast showing peripheral enhancement (white arrows)

Fig. 3

Photomicrograph showing fibroblasts, lymphocytes and foreign body type of giant cells in tophaceous gout.

T2W image showing hyperintense L5-S1 disc Axial MRI with contrast showing peripheral enhancement (white arrows) Photomicrograph showing fibroblasts, lymphocytes and foreign body type of giant cells in tophaceous gout. Spinal involvement in gout is rare. Monosodium urate crystals can deposit at ligamentum flavum, facets, epidural space, intradural compartment, discovertebral junction, lamina, pedicle and neural foramen1. Gouty tophi can result in degenerative spondylosis, discovertebral erosions, bone destruction leading to joint subluxation, spinal deformities, spontaneous fusion or pathological fractures. Patients could present with features of spinal stenosis, lumbar radiculopathy, spondylolisthesis, cauda equina syndrome or spinal infection2. This patient had vertebral end plate erosions with retrolisthesis and features mimicking infection. In patients with history of hyperuricemea presenting with back pain or other spinal symptoms, tophaceous gout of the spine should be included as a differential diagnosis.
  2 in total

1.  Tophaceous gout of the spine: MR imaging features.

Authors:  C-Y Hsu; T T-F Shih; K-M Huang; P-Q Chen; J-J Sheu; Y-W Li
Journal:  Clin Radiol       Date:  2002-10       Impact factor: 2.350

2.  Topacheous gout as a rare cause of spinal stenosis in the lumbar region. Case report.

Authors:  Joseph Kelly; Chris Lim; Mahmoud Kamel; Catherine Keohane; Michael O'Sullivan
Journal:  J Neurosurg Spine       Date:  2005-02
  2 in total
  1 in total

Review 1.  Gout in the Spine: Imaging, Diagnosis, and Outcomes.

Authors:  Michael Toprover; Svetlana Krasnokutsky; Michael H Pillinger
Journal:  Curr Rheumatol Rep       Date:  2015-12       Impact factor: 4.592

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.